I-J Oh - Department of Internal Medicine, Chonnam National University Medical School, Hwasun-gun Jeollanam-do, Republic of Korea

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 23 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Early Diagnosis of Lung Cancer by Detecting Tumor Originated Deoxyribo Nucleic Acid (DNA) Fragments Using Plasma Cell-free DNA Methylome and Fragmentome Profiles

C.-S. Yoon, J.Y. Yoon, H.K. Park,H.-J. Oh,Y.-C. Kim, H.-J. Cho, Y.J. Kim, H. Jeon, S. Jeon, S.-H. Lee,B.-C. Kim,I.-J. Oh

B109. DIVING INTO DISCOVERY: CURRENTS OF BASIC SCIENCE AND IMMUNOTHERAPIES IN LUNG CANCER (2024)

引用0浏览0引用

24P Efficacy and safety of 1st generation EGFR TKI retreatment in EGFR mutation-positive, T790M-negative patients previously treated with 1st or 2nd generation EGFR TKI and cytotoxic chemotherapy

S.Y. Lee,J. Choi,J.C. Lee, C.M. Choi,I.A. Kim,K.Y. Lee,J.E. Lee, S.H. Jang, S.H. Yoon,I-J. Oh, S.H. Lee, E.Y. Kim

Journal of Thoracic Oncologyno. 4 (2023): S54-S54

引用0浏览0引用

P2.09-08 Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial

Y. Jang,C.-M. Choi,I.-J. Oh, Y.-C. Kim, W. Ji, J.C. Lee

Journal of Thoracic Oncologyno. 11 (2023): S334-S335

引用0浏览0引用

Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial

Y. Jang, C. -M. Choi,I. -J. Oh, Y. -C. Kim, W. Ji, J. C. Lee

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S334-S335

引用0浏览0引用

Combination of two distinct subsets of peripheral blood CD8+T cells from patients with NSCLC predicts response outcome to immune checkpoint inhibitor therapy

J-H. Cho, S-W. Lee, J. S. Yun,H-O. Kim,H. Cho, S. Y. Song,I-J. Oh

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC

S. Y. Lee, C. -M. Choi,Y. S. Chang, K. Y. Lee,S. J. Kim, S. H. Yang, J. S. Ryu, J. E. Lee,J. Y. Park, S. Y. Lee,Y. -C. Kim,I. -J. Oh,

Journal of Thoracic Oncologyno. 9 (2022): S471-S471

引用0浏览0引用

EP08.02-142 Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC

S.Y. Lee, C.-M. Choi, Y.S. Chang, K.Y. Lee,S.J. Kim, S.H. Yang, J.S. Ryu, J.E. Lee,J.Y. Park, S.Y. Lee,Y.-C. Kim,I.-J. Oh,

Journal of Thoracic Oncologyno. 9 (2022): S471

引用0浏览0引用

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

J Wolf,Å Helland,I-J Oh, M R Migliorino, R Dziadziuszko,A Wrona,J de Castro, J Mazieres, F Griesinger, M Chlistalla,A Cardona, T Ruf,

ESMO Open（2022）

引用11浏览0WOS引用

968TiP A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial)

S.Y. Lee,J.E. Lee,C-M. Choi,I-J. Oh,K. Lee,T. Jang,S.H. Lee,E.Y. Kim,D.W. Park,S.H. Park

Annals of Oncology (2022): S990-S990

引用0浏览0引用

A phase II open-label, multicentre study to assess the anti-tumour activity of afatinib in patients with activating epidermal growth factor receptor mutation (EGFRm) from circulating tumour DNA (CtDNA)

Y-C. Kim,C-K. Park,I-J. Oh,S. Y. Lee, J. C. Lee,C-M. Choi,S. Y. Lee,T. W. Jang

Annals of Oncology（2019）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn